<p>Hyderabad, India and Princeton, NJ, USA. February 12,2019&amp;mdash;<a href="https://en.wikipedia.org/wiki/Dr._Reddy&#039;s_Laboratories">Dr. Reddy&amp;rsquo;s Laboratories Ltd</a>. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy&amp;rsquo;s”) today announced the launch ofTadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tadalafil) Tabletsin the United States market, approved by the U.S. Food and Drug Administration (USFDA).</p><p>The Adcirca brand and generic had U.S. sales of approximately $490 million MAT for the most recent twelve months ending in November 2018 according to IMS Health*.</p><p>Dr. Reddy&amp;rsquo;s Tadalafil Tablets are available in 20 mg with 60 count bottle size.  Adcircais a trademark of Eli Lilly and Company.</p><p><strong>About Dr. Reddy&amp;rsquo;s:</strong> <a href="https://en.wikipedia.org/wiki/Dr._Reddy&#039;s_Laboratories">Dr. Reddy&amp;rsquo;s Laboratories Ltd.</a> (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &amp;amp; Active Ingredients, Global Generics and Proprietary Products &amp;ndash; Dr. Reddy&amp;rsquo;s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy&amp;rsquo;s operates in markets across the globe. Our major markets include &amp;ndash; USA, India, Russia &amp;amp; CIS countries, and Europe. For more information, log on to:<a href="http://www.drreddys.com">www.drreddys.com</a></p>